雷贝拉唑联合伊托必利治疗反流性食道炎87例临床疗效观察

目的观察雷贝拉唑联合伊托必利治疗反流性食道炎的临床效果及不良反应，为临床反流性食道炎的治疗提供依据。方法对2010年4月～2011年12月入院治疗的174例反流性食道炎患者按入院顺序随机分为对照组和观察组各87例，对照组给予雷贝拉唑治疗，观察组给予雷贝拉唑联合伊托必利治疗，治疗4周后比较两组患者临床症状积分变化，总有效率以及不同时间的疗效和复发率，并对两组患者内镜病变改善情况进行比较，同时比较两种治疗方案的不良反应情况。结果观察组患者烧心、胸骨疼痛、胃脘胀痛等临床症状积分明显低于对照组，差异有统计学意义（均P〈0．05）；观察组患者治疗4周后总有效率为90．8％，明显高于对照组（79．3％），差异有统计学意义（P〈0．05）；观察组在第12、24和48周的临床治愈率明显高于对照组，且复发率明显低于对照组，差异有统计学意义（P〈O．05）；观察组患者内镜下食管病变改善总有效率为92．0％，对照组仅为75．9％，两组比较差异有统计学意义（P〈0．05）；两组治疗方案均没有出现严重不良反应，患者耐受性良好。结论雷贝拉唑联合伊托必利治疗反流性食道炎临床效果显著，能明显改善患者临床症状，好于单一用药，且复发率低，安全性良好，值得临床推广应用。

Clinical effect of rabeprazole and itopride on 78 reflux esophagitis

Objective To study the clinical effect and adverse effect of rabeprazole and itopridein treatment of re- flux esophagitis. Methods 174 patients with bronchial asthma from were randomly divided into treatment group and con- trol group. All the patients were treated with Rabeprazole and the patients in treatment group were treated with Rabe- prazole and Itopride. The clinical symptom score, total clinical effect, the curative effect of different time and recurrence rate, the gastroesophageal pathology improvement and the adverse effect was compared. Results Heartburn, chest pain, the diagnosis pain and clinical score in treatment group were significantly lower than the control group, the difference was statistically significant（P〈0.05）, the total effective rate of treatment group was 90.8~, the differences were statistical- ly significant between the two groups（P〈0.05）. Clinical cure rate in week 12, 24 and 48 week was significantly higher than the control group, and the recurrence rate was lower than the control group（P〈0.05）. Endoscopic esophagus le- sions in treatment group was improved the total effective rate was 92. 0%, the control period is only 75.9%, there is sta-tistical significance（P〈0.05）; the two group were no serious adverse reactions, patients were well tolerated. Conclusion Rabeprazole with Itopride will benefit in treatment of reflux esophagitis, the clinical effect is remarkable, and the clinical symptom is more apparent, the clinical total effective rate is higher, and the recurrence rate is low, the esophagitis is ob- viously improvement.